Patents by Inventor Andrew Stephen Robert Jennings

Andrew Stephen Robert Jennings has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolone compounds having human neutrophil elastase inhibitory properties
    Patent number: 10172830
    Abstract: Pyrazolone derivatives of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of diseases or conditions in which HNE is implicated.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: January 8, 2019
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Jonathan Mark Sutton, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • Compounds
    Patent number: 10023558
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: July 17, 2018
    Assignee: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark Sutton, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • NOVEL COMPOUNDS
    Publication number: 20180009787
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated
    Type: Application
    Filed: September 22, 2017
    Publication date: January 11, 2018
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark SUTTON, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • Compounds
    Patent number: 9862706
    Abstract: Imidazolone and pyrazolone derivatives of formula (I) described herein exhibit human neutrophil elastase inhibitory properties and are useful for the therapy of diseases and conditions in which HNE is implicated.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: January 9, 2018
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Carmelida Capaldi, Elisabetta Armani, Andrew Stephen Robert Jennings
  • NOVEL COMPOUNDS
    Publication number: 20170342056
    Abstract: Imidazolone and pyrazolone derivatives of formula (I) described herein exhibit human neutrophil elastase inhibitory properties and are useful for the therapy of diseases and conditions in which HNE is implicated.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Carmelida CAPALDI, Elisabetta ARMANI, Andrew Stephen Robert JENNINGS
  • NOVEL COMPOUNDS
    Publication number: 20170340611
    Abstract: Pyrazolone derivatives of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of diseases or conditions in which HNE is implicated.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 30, 2017
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Jonathan Mark SUTTON, Robert Andrew HEALD, Andrew Stephen Robert JENNINGS, Carmelida CAPALDI, Elisabetta ARMANI
  • Compounds
    Patent number: 9802919
    Abstract: Compounds of formula (I) defined herein exhibit human neutrophil elastase inhibitory properties and are useful for the treatment of disease or conditions in which HNE is implicated.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: October 31, 2017
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Jonathan Mark Sutton, Robert Andrew Heald, Andrew Stephen Robert Jennings, Carmelida Capaldi, Elisabetta Armani
  • Derivatives of [1, 2, 4] triazolo [4, 3-a] pyridine as P38—MAP kinase inhibitors
    Patent number: 9573949
    Abstract: Mitogen activated protein kinase (MAPK) inhibitors disclosed herein are useful for the treatment of diseases of the respiratory tract, such as chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy, and airways disease that is associated with pulmonary hypertension.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: February 21, 2017
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9527846
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: December 27, 2016
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9440974
    Abstract: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: September 29, 2015
    Date of Patent: September 13, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Lilian Alcaraz, Christopher Hurley, Andrew Peter Cridland, Andrew Stephen Robert Jennings
  • KINASE INHIBITORS
    Publication number: 20160229852
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: April 18, 2016
    Publication date: August 11, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil VAN NIEL, Nicholas Charles RAY, Lilian ALCARAZ, Terry Aaron PANCHAL, Andrew Stephen Robert JENNINGS, Elisabetta ARMANI, Andrew Peter CRIDLAND, Christopher HURLEY
  • DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS
    Publication number: 20160108040
    Abstract: This invention relates to compounds selected in the group consisting of compounds of formula (Ia) to (Id) and compositions, that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: June 6, 2013
    Publication date: April 21, 2016
    Applicant: CHIESI FARMACEUTICI S.P.A.
    Inventors: Lilian ALCARAZ, Terry Aaron PANCHAL, Andrew Stephen, Robert JENNINGS, Andrew Peter CRIDLAND, Christopher HURLEY
  • Kinase inhibitors
    Patent number: 9315503
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: August 6, 2015
    Date of Patent: April 19, 2016
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • KINASE INHIBITORS
    Publication number: 20160016953
    Abstract: Compounds of formula (I) described herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract
    Type: Application
    Filed: September 29, 2015
    Publication date: January 21, 2016
    Applicant: CHIESI FARMACEUTICI S.p.A
    Inventors: Lilian ALCARAZ, Christopher HURLEY, Andrew Peter CRIDLAND, Andrew Stephen Robert JENNINGS
  • KINASE INHIBITORS
    Publication number: 20150344475
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: August 6, 2015
    Publication date: December 3, 2015
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil VAN NIEL, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9181242
    Abstract: This invention relates to compounds and compositions that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: June 5, 2014
    Date of Patent: November 10, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Lilian Alcaraz, Christopher Hurley, Andrew Peter Cridland, Andrew Stephen Robert Jennings
  • Kinase inhibitors
    Patent number: 9145413
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: July 14, 2014
    Date of Patent: September 29, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9139584
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: September 22, 2015
    Assignee: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley
  • Kinase inhibitors
    Patent number: 9029373
    Abstract: Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Grant
    Filed: August 5, 2014
    Date of Patent: May 12, 2015
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Andrew Peter Cridland, Christopher Hurley, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani
  • KINASE INHIBITORS
    Publication number: 20150080375
    Abstract: Compounds of formula (I) and pharmaceutically acceptable salts thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.
    Type: Application
    Filed: October 14, 2014
    Publication date: March 19, 2015
    Applicant: CHIESI FARMACEUTICI S.p.A.
    Inventors: Monique Bodil Van Niel, Nicholas Charles Ray, Lilian Alcaraz, Terry Aaron Panchal, Andrew Stephen Robert Jennings, Elisabetta Armani, Andrew Peter Cridland, Christopher Hurley